ArticleAnnals of medicine and surgery (2012)2025
Evaluating the effectiveness of nicardipine prolonged-release implants in patients with subarachnoid hemorrhage: a meta-analysis and meta-regression analysis.
Article in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Erratum: Evaluating the effectiveness of nicardipine prolonged-release implants in patients with subarachnoid hemorrhage: a meta-analysis and meta-regression analysis.Annals of medicine and surgery (2012) · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction and importance: Subarachnoid hemorrhage (SAH) is a critical condition with high morbidity and mortality, often complicated by cerebral vasospasm and delayed cerebral ischemia (DCI). Nicardipine, a calcium channel blocker, has shown promise in mitigating these risks. This meta-analysis evaluates the effectiveness and safety of nicardipine prolonged-release implants in reducing SAH complications. Methods: A comprehensive literature search was conducted in PubMed, Cochrane Library, Embase, and ClinicalTrials.gov, identifying seven eligible studies involving 775 patients with SAH. Randomized controlled trials (RCTs) and observational studies were included. The primary outcome was the incidence of cerebral vasospasm, while secondary outcomes included DCI and delayed ischemic neurologic deficit (DIND). Risk ratios (RR) with 95% confidence intervals (CI) were calculated using random-effects meta-analysis. Results: Nicardipine implants significantly reduced the risk of cerebral vasospasm (RR = 0.38, 95% CI [0.23, 0.61], Conclusion: Nicardipine prolonged-release implants are effective in reducing the incidence of cerebral vasospasm and DCI in SAH patients, with potential benefits in preventing these complications. However, they do not significantly impact functional outcomes, indicating the need for complementary rehabilitation strategies. Further large-scale studies are needed to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.